(Q35817013)

10 August 2017

1 reference

title

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics (English)

1 reference

10 August 2017

1 reference

1 reference

1 reference

Brian P Kearney

1

1 reference

10 August 2017

John F Flaherty

series ordinal

2

1 reference

10 August 2017

Jaymin Shah

series ordinal

3

1 reference

10 August 2017

publication date

1 January 2004

1 reference

Clinical Pharmacokinetics

10 August 2017

published in

1 reference

10 August 2017

volume

43

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

595-612

1 reference

Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.

10 August 2017

cites work

1 reference

12 December 2020

Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children

1 reference

12 December 2020

Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA

1 reference

12 December 2020

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study

1 reference

12 December 2020

Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine

1 reference

12 December 2020

Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir

1 reference

12 December 2020

Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells

1 reference

12 December 2020

Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.

1 reference

12 December 2020

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial

1 reference

12 December 2020

Renal safety of tenofovir in HIV treatment-experienced patients.

1 reference

12 December 2020

Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.

1 reference

12 December 2020

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults

1 reference

12 December 2020

Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice

1 reference

12 December 2020

Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs

1 reference

12 December 2020

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020

Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals

1 reference

12 December 2020

Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures.

1 reference

12 December 2020

10.2165/00003088-200443090-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1052180346

0 references

1 reference